BIOBio-rad Laboratories, Inc.
Bio-rad Laboratories, Inc. (BIO) sells diagnostic and life sciences tools, primarily in clinical and research settings. The company’s next catalyst is Oct 22, 2026 — Q3 2026 Earnings Release, which will test its ability to maintain revenue growth and stabilize margins after a recent earnings miss.
- Bio-rad operates in a fragmented, capital-intensive market with high R&D and regulatory costs.
- The company’s recent Q2 2026 earnings report was in line with expectations, but its long-term profitability remains under pressure.
- The business is heavily dependent on government and institutional buyers, which exposes it to policy and funding shifts.
The Read
5% after missing Q4 2025 earnings and reporting shrinking margins, but rallied 16%.
The schedule
- Thu22Oct
The earnings release will test the company's cash flow and product performance, especially in light of the recent news about brain injuries. This will differ from the last earnings print where the focus was on macroeconomic factors.
- Tue9Feb
The earnings release will test the company's ability to maintain its product mix and cash flow, especially in light of the recent news about brain injuries. This will differ from the last earnings print where the focus was on macroeconomic factors.
- Thu6May
The earnings release will test the company's ability to maintain its product mix and cash flow, especially in light of the recent news about brain injuries. This will differ from the last earnings print where the focus was on macroeconomic factors.
- Tue3Aug
The earnings release will test the company's ability to maintain its product mix and cash flow, especially in light of the recent news about brain injuries. This will differ from the last earnings print where the focus was on macroeconomic factors.
Past
- Fri31Jul
Actual outcome: Bull
Bio-Rad Laboratories reported its Q2 2026 financial results on August 4, delivering an EPS of -$19.55 that perfectly matched consensus estimates. The in-line earnings report sustained the stock's strong upward momentum from late July, allowing shares to easily surpass the $312.03 bull target and close at $334.71.
- Tue30Jun
Actual outcome: Bull · $305.96 at outcome
Bio-Rad shares rallied well past the $290 bull target, driven by news of activist involvement from Elliott Management. The activist presence highlighted significant value-unlocking potential for the company, including a strategic shift toward revenue-generating bolt-on M&A, R&D rationalization, and the potential monetization of its $5 billion Sartorius stake.
- Thu12Feb
Actual outcome: Bear · $270.67 at outcome
Bio-Rad missed Q4 EPS estimates ($2.51 vs. $2.57) and reported shrinking margins, overshadowing a slight revenue beat in Clinical Diagnostics. The stock fell significantly below the bear floor as the results and 2026 outlook failed to confirm the anticipated operational recovery in the Life Science segment, which had been the primary focus for investors following a weak 2025.
